 Ronina Covar
Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 77 | 2023 | 2066 | 6.180 |
Why?
| | Anti-Asthmatic Agents | 29 | 2021 | 350 | 3.290 |
Why?
| | Bronchial Provocation Tests | 6 | 2022 | 53 | 1.710 |
Why?
| | Bronchodilator Agents | 15 | 2019 | 249 | 1.590 |
Why?
| | Adrenal Cortex Hormones | 15 | 2022 | 509 | 1.560 |
Why?
| | Respiratory Sounds | 12 | 2022 | 111 | 1.350 |
Why?
| | Budesonide | 9 | 2016 | 87 | 1.190 |
Why?
| | Bronchial Hyperreactivity | 5 | 2018 | 96 | 1.140 |
Why?
| | Eosinophilia | 2 | 2023 | 186 | 0.920 |
Why?
| | Nedocromil | 5 | 2016 | 32 | 0.860 |
Why?
| | Albuterol | 10 | 2018 | 105 | 0.860 |
Why?
| | Administration, Inhalation | 22 | 2022 | 644 | 0.850 |
Why?
| | Glucocorticoids | 11 | 2019 | 552 | 0.840 |
Why?
| | Androstadienes | 7 | 2016 | 97 | 0.830 |
Why?
| | Lung | 8 | 2022 | 3672 | 0.830 |
Why?
| | Respiratory Function Tests | 13 | 2018 | 535 | 0.820 |
Why?
| | Fluticasone | 10 | 2019 | 87 | 0.820 |
Why?
| | Forced Expiratory Volume | 16 | 2022 | 516 | 0.700 |
Why?
| | Respiratory Mechanics | 1 | 2020 | 56 | 0.690 |
Why?
| | Anti-Inflammatory Agents | 10 | 2016 | 448 | 0.670 |
Why?
| | Leukotriene Antagonists | 6 | 2016 | 41 | 0.650 |
Why?
| | Mediastinal Emphysema | 1 | 2018 | 5 | 0.610 |
Why?
| | Nitric Oxide | 6 | 2023 | 832 | 0.590 |
Why?
| | Child | 49 | 2023 | 18489 | 0.570 |
Why?
| | Double-Blind Method | 19 | 2021 | 1659 | 0.520 |
Why?
| | Acetates | 7 | 2014 | 96 | 0.510 |
Why?
| | Quinolines | 7 | 2014 | 129 | 0.490 |
Why?
| | Marijuana Smoking | 1 | 2018 | 224 | 0.480 |
Why?
| | Eosinophils | 6 | 2023 | 282 | 0.470 |
Why?
| | Child, Preschool | 35 | 2022 | 9133 | 0.470 |
Why?
| | Humans | 85 | 2023 | 115589 | 0.460 |
Why?
| | Precision Medicine | 4 | 2021 | 344 | 0.450 |
Why?
| | Sputum | 4 | 2023 | 290 | 0.430 |
Why?
| | Adrenergic beta-Agonists | 4 | 2013 | 129 | 0.410 |
Why?
| | Biomarkers | 10 | 2023 | 3467 | 0.380 |
Why?
| | Cannabis | 1 | 2018 | 381 | 0.380 |
Why?
| | Phenotype | 4 | 2020 | 2829 | 0.380 |
Why?
| | Adolescent | 31 | 2022 | 17890 | 0.360 |
Why?
| | Eicosapentaenoic Acid | 1 | 2010 | 28 | 0.360 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2021 | 1216 | 0.350 |
Why?
| | Docosahexaenoic Acids | 1 | 2010 | 69 | 0.350 |
Why?
| | Male | 53 | 2020 | 55949 | 0.340 |
Why?
| | Salmeterol Xinafoate | 6 | 2019 | 41 | 0.340 |
Why?
| | Ibuprofen | 2 | 2021 | 73 | 0.310 |
Why?
| | Female | 52 | 2020 | 59913 | 0.310 |
Why?
| | Spirometry | 9 | 2022 | 253 | 0.290 |
Why?
| | Drug Therapy, Combination | 7 | 2016 | 962 | 0.280 |
Why?
| | Breath Tests | 3 | 2023 | 83 | 0.270 |
Why?
| | Antioxidants | 1 | 2010 | 533 | 0.270 |
Why?
| | Treatment Outcome | 15 | 2019 | 9159 | 0.270 |
Why?
| | Disease Progression | 9 | 2018 | 2418 | 0.270 |
Why?
| | Pulmonary Ventilation | 1 | 2005 | 68 | 0.240 |
Why?
| | Microbiota | 2 | 2023 | 652 | 0.230 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 1098 | 0.230 |
Why?
| | Severity of Illness Index | 12 | 2021 | 2578 | 0.230 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 180 | 0.230 |
Why?
| | Beclomethasone | 2 | 2015 | 25 | 0.220 |
Why?
| | Ribonucleases | 1 | 2003 | 53 | 0.220 |
Why?
| | Mycobiome | 1 | 2023 | 6 | 0.220 |
Why?
| | Prospective Studies | 8 | 2023 | 6264 | 0.220 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2005 | 293 | 0.210 |
Why?
| | Larynx | 1 | 2023 | 48 | 0.210 |
Why?
| | Dietary Supplements | 2 | 2020 | 458 | 0.210 |
Why?
| | Respiration | 1 | 2003 | 177 | 0.210 |
Why?
| | Antigens, Dermatophagoides | 1 | 2022 | 10 | 0.200 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 301 | 0.200 |
Why?
| | Muscarinic Antagonists | 1 | 2022 | 27 | 0.200 |
Why?
| | Azithromycin | 2 | 2015 | 80 | 0.200 |
Why?
| | Prednisone | 4 | 2016 | 232 | 0.190 |
Why?
| | Airway Obstruction | 2 | 2022 | 168 | 0.190 |
Why?
| | Models, Biological | 1 | 2008 | 1646 | 0.190 |
Why?
| | Infant | 15 | 2022 | 7979 | 0.190 |
Why?
| | Vitamin D Deficiency | 2 | 2020 | 159 | 0.180 |
Why?
| | Cross-Over Studies | 6 | 2019 | 434 | 0.180 |
Why?
| | Cholecalciferol | 1 | 2020 | 47 | 0.180 |
Why?
| | Leukocyte Count | 4 | 2019 | 294 | 0.170 |
Why?
| | Methacholine Chloride | 3 | 2022 | 47 | 0.170 |
Why?
| | Mometasone Furoate | 1 | 2019 | 5 | 0.170 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 34 | 0.170 |
Why?
| | Social Class | 1 | 2021 | 210 | 0.170 |
Why?
| | Risk Factors | 8 | 2016 | 8697 | 0.170 |
Why?
| | Vitamins | 1 | 2020 | 151 | 0.170 |
Why?
| | Tiotropium Bromide | 1 | 2019 | 19 | 0.160 |
Why?
| | Symbiosis | 1 | 2019 | 65 | 0.160 |
Why?
| | Minority Groups | 1 | 2021 | 230 | 0.160 |
Why?
| | Population | 1 | 2018 | 28 | 0.160 |
Why?
| | Cyclopropanes | 7 | 2014 | 81 | 0.150 |
Why?
| | Acetaminophen | 2 | 2021 | 237 | 0.150 |
Why?
| | Education | 1 | 2018 | 99 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2021 | 1405 | 0.150 |
Why?
| | Sulfides | 7 | 2014 | 94 | 0.150 |
Why?
| | Adult | 13 | 2023 | 30719 | 0.140 |
Why?
| | Patient Selection | 1 | 2021 | 654 | 0.140 |
Why?
| | Airway Remodeling | 1 | 2016 | 60 | 0.140 |
Why?
| | Benzyl Alcohols | 1 | 2016 | 2 | 0.140 |
Why?
| | Chlorobenzenes | 1 | 2016 | 8 | 0.140 |
Why?
| | Tomography, X-Ray Computed | 3 | 2021 | 2392 | 0.140 |
Why?
| | Anti-Bacterial Agents | 3 | 2015 | 1483 | 0.140 |
Why?
| | Child Care | 1 | 2016 | 23 | 0.130 |
Why?
| | Eczema | 2 | 2014 | 82 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 3 | 2016 | 2125 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2019 | 1870 | 0.130 |
Why?
| | Bronchoconstrictor Agents | 2 | 2006 | 14 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2016 | 465 | 0.120 |
Why?
| | Obesity | 2 | 2017 | 2517 | 0.120 |
Why?
| | Lectins | 1 | 2014 | 46 | 0.120 |
Why?
| | Secondary Prevention | 1 | 2015 | 223 | 0.120 |
Why?
| | Adipokines | 1 | 2014 | 43 | 0.120 |
Why?
| | Drug Administration Schedule | 5 | 2016 | 724 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 273 | 0.120 |
Why?
| | Prognosis | 2 | 2016 | 3339 | 0.120 |
Why?
| | Teaching | 1 | 2016 | 224 | 0.110 |
Why?
| | Overweight | 1 | 2017 | 469 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2800 | 0.110 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 242 | 0.110 |
Why?
| | Virus Diseases | 1 | 2015 | 200 | 0.110 |
Why?
| | Age Factors | 3 | 2016 | 2907 | 0.110 |
Why?
| | Body Height | 2 | 2011 | 180 | 0.110 |
Why?
| | Disease Management | 1 | 2016 | 563 | 0.110 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 682 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2016 | 941 | 0.100 |
Why?
| | Genomics | 1 | 2016 | 646 | 0.100 |
Why?
| | Multicenter Studies as Topic | 2 | 2018 | 249 | 0.100 |
Why?
| | Recurrence | 3 | 2016 | 952 | 0.100 |
Why?
| | Food Hypersensitivity | 1 | 2016 | 254 | 0.100 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 323 | 0.100 |
Why?
| | Schools | 2 | 2018 | 400 | 0.100 |
Why?
| | Young Adult | 4 | 2022 | 10470 | 0.100 |
Why?
| | Dexamethasone | 2 | 2005 | 316 | 0.100 |
Why?
| | Immunoglobulin E | 3 | 2015 | 328 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2416 | 0.090 |
Why?
| | Research Design | 3 | 2021 | 946 | 0.090 |
Why?
| | Vital Capacity | 3 | 2022 | 277 | 0.090 |
Why?
| | Symptom Flare Up | 2 | 2020 | 40 | 0.090 |
Why?
| | Time Factors | 3 | 2008 | 6165 | 0.080 |
Why?
| | Drug Synergism | 2 | 2008 | 317 | 0.080 |
Why?
| | Caregivers | 1 | 2016 | 713 | 0.080 |
Why?
| | Skin Tests | 2 | 2015 | 130 | 0.080 |
Why?
| | Growth | 2 | 2018 | 56 | 0.080 |
Why?
| | Immunotherapy | 1 | 2012 | 479 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 815 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1198 | 0.070 |
Why?
| | Adenosine Monophosphate | 1 | 2007 | 49 | 0.070 |
Why?
| | Hypersensitivity | 2 | 2018 | 260 | 0.070 |
Why?
| | Respiratory Tract Diseases | 1 | 2008 | 142 | 0.070 |
Why?
| | Inflammation | 4 | 2005 | 2499 | 0.070 |
Why?
| | Drug Resistance | 2 | 2018 | 162 | 0.070 |
Why?
| | School Health Services | 1 | 2009 | 206 | 0.070 |
Why?
| | Cohort Studies | 3 | 2011 | 4944 | 0.070 |
Why?
| | Weight Gain | 1 | 2009 | 453 | 0.070 |
Why?
| | Drug Combinations | 2 | 2019 | 289 | 0.070 |
Why?
| | Regression Analysis | 1 | 2008 | 959 | 0.070 |
Why?
| | Incidence | 2 | 2016 | 2335 | 0.060 |
Why?
| | Treatment Failure | 2 | 2020 | 332 | 0.060 |
Why?
| | Administration, Oral | 3 | 2013 | 734 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2008 | 1440 | 0.060 |
Why?
| | Bone Density | 1 | 2008 | 432 | 0.060 |
Why?
| | Biopsy | 2 | 2005 | 1056 | 0.060 |
Why?
| | Cross-Sectional Studies | 5 | 2015 | 4435 | 0.060 |
Why?
| | Global Health | 1 | 2006 | 290 | 0.060 |
Why?
| | Lymphocyte Activation | 2 | 2005 | 1057 | 0.060 |
Why?
| | Logistic Models | 2 | 2010 | 1856 | 0.060 |
Why?
| | Eosinophil Granule Proteins | 1 | 2003 | 20 | 0.060 |
Why?
| | Age of Onset | 3 | 2014 | 450 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2009 | 771 | 0.050 |
Why?
| | Age Distribution | 1 | 2004 | 341 | 0.050 |
Why?
| | Sex Distribution | 1 | 2004 | 337 | 0.050 |
Why?
| | Health Status | 1 | 2008 | 728 | 0.050 |
Why?
| | Environmental Exposure | 1 | 2006 | 378 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 390 | 0.050 |
Why?
| | Fungi | 1 | 2023 | 122 | 0.050 |
Why?
| | Clarithromycin | 1 | 2001 | 25 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 58 | 0.050 |
Why?
| | Research | 2 | 2022 | 396 | 0.050 |
Why?
| | Bronchi | 1 | 2003 | 250 | 0.050 |
Why?
| | Trachea | 1 | 2023 | 233 | 0.050 |
Why?
| | Blood Proteins | 1 | 2003 | 238 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2005 | 1357 | 0.050 |
Why?
| | Cushing Syndrome | 1 | 2000 | 10 | 0.050 |
Why?
| | Dyspnea | 1 | 2022 | 223 | 0.050 |
Why?
| | Adrenal Glands | 1 | 2000 | 72 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 234 | 0.040 |
Why?
| | Advisory Committees | 1 | 2021 | 208 | 0.040 |
Why?
| | Geography | 1 | 2021 | 181 | 0.040 |
Why?
| | Moraxella | 1 | 2019 | 5 | 0.040 |
Why?
| | Carnobacteriaceae | 1 | 2019 | 3 | 0.040 |
Why?
| | Medication Adherence | 2 | 2019 | 538 | 0.040 |
Why?
| | Streptococcus | 1 | 2019 | 23 | 0.040 |
Why?
| | Exercise Test | 1 | 2022 | 539 | 0.040 |
Why?
| | Middle Aged | 6 | 2019 | 26998 | 0.040 |
Why?
| | Staphylococcus | 1 | 2019 | 69 | 0.040 |
Why?
| | Animals | 2 | 2022 | 32102 | 0.040 |
Why?
| | Nasal Mucosa | 1 | 2019 | 94 | 0.040 |
Why?
| | Prevalence | 1 | 2005 | 2264 | 0.040 |
Why?
| | United States | 3 | 2021 | 12295 | 0.040 |
Why?
| | Allergens | 1 | 2022 | 418 | 0.040 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2018 | 35 | 0.040 |
Why?
| | Absenteeism | 1 | 2018 | 40 | 0.040 |
Why?
| | Sex Factors | 2 | 2016 | 1736 | 0.040 |
Why?
| | Vitamin D | 1 | 2020 | 341 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2005 | 1756 | 0.040 |
Why?
| | Netherlands | 1 | 2016 | 64 | 0.040 |
Why?
| | Bacteria | 1 | 2023 | 729 | 0.030 |
Why?
| | Pharmacokinetics | 1 | 2016 | 26 | 0.030 |
Why?
| | Airway Resistance | 2 | 2006 | 33 | 0.030 |
Why?
| | Placebo Effect | 1 | 2016 | 51 | 0.030 |
Why?
| | Plethysmography | 2 | 2006 | 103 | 0.030 |
Why?
| | Exhalation | 1 | 2015 | 35 | 0.030 |
Why?
| | Fever | 1 | 2016 | 280 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 156 | 0.030 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2014 | 17 | 0.030 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 1 | 2014 | 12 | 0.030 |
Why?
| | Needs Assessment | 1 | 2016 | 318 | 0.030 |
Why?
| | Leukotriene E4 | 1 | 2013 | 27 | 0.030 |
Why?
| | Anaphylaxis | 1 | 2016 | 148 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1127 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 278 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2014 | 184 | 0.030 |
Why?
| | Acute Disease | 1 | 2015 | 914 | 0.030 |
Why?
| | Hypertension | 1 | 2000 | 1064 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1000 | 0.030 |
Why?
| | Colorado | 2 | 2014 | 4113 | 0.030 |
Why?
| | Prednisolone | 1 | 2011 | 77 | 0.020 |
Why?
| | Pain | 1 | 2016 | 712 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1217 | 0.020 |
Why?
| | Body Mass Index | 1 | 2017 | 1971 | 0.020 |
Why?
| | Curriculum | 1 | 2016 | 852 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 1918 | 0.020 |
Why?
| | Poverty | 1 | 2012 | 448 | 0.020 |
Why?
| | Eosinophil Cationic Protein | 1 | 2008 | 9 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 4440 | 0.020 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 53 | 0.020 |
Why?
| | Retrospective Studies | 3 | 2014 | 12608 | 0.020 |
Why?
| | Factor Analysis, Statistical | 1 | 2008 | 261 | 0.020 |
Why?
| | Insurance, Health | 1 | 2009 | 246 | 0.020 |
Why?
| | Body Weight | 1 | 2011 | 867 | 0.020 |
Why?
| | Birth Weight | 1 | 2009 | 438 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 2006 | 45 | 0.020 |
Why?
| | Oscillometry | 1 | 2006 | 33 | 0.020 |
Why?
| | Biomedical Research | 1 | 2012 | 588 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2005 | 77 | 0.020 |
Why?
| | Respiratory Hypersensitivity | 1 | 2005 | 63 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2000 | 3254 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 1805 | 0.010 |
Why?
| | Basement Membrane | 1 | 2003 | 29 | 0.010 |
Why?
| | Reference Values | 1 | 2005 | 744 | 0.010 |
Why?
| | Interleukins | 1 | 2005 | 238 | 0.010 |
Why?
| | Fractures, Bone | 1 | 2008 | 372 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1044 | 0.010 |
Why?
| | Immune Tolerance | 1 | 2005 | 332 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2003 | 150 | 0.010 |
Why?
| | Bronchoscopy | 1 | 2003 | 245 | 0.010 |
Why?
| | Steroids | 1 | 2002 | 147 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1718 | 0.010 |
Why?
| | Gene Expression | 1 | 2005 | 1436 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 4665 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2005 | 2574 | 0.010 |
Why?
| | Pilot Projects | 1 | 2001 | 1377 | 0.010 |
Why?
| | Aged | 2 | 2005 | 19250 | 0.010 |
Why?
|
|
Covar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|